Berenberg keeps EUR 3.60 target for Evotec stock

Published on 10/23/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock costs EUR 2.83 on October 23, 2026, 0.35 percent below Xetra. Full results arrive November 5, 2026 after EUR 465.0 million.

Targets results and valuation

Berenberg maintained its EUR 3.60 target on October 16, 2026.
Evotec projected EUR 465.0 million in nine-month revenue for 2026.
Evotec stock trades at EUR 2.83 at 10:29 a.m. CEST at Lang & Schwarz on October 23, 2026, 0.35 percent below the Xetra close of October 22, 2026.
Full third-quarter and nine-month results are scheduled for November 5, 2026.

Extreme Makroaufnahme einer leuchtend blauen kristallinen Molekülstruktur — Makroaufnahme einer kristallinen Molekülstruktur verweist auf die Wirkstoffforschung von Evotec SE, ISIN DE0005664809, leuchtendes Blau, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) is trading at EUR 2.83 at Lang & Schwarz on October 23, 2026, 0.35 percent below the Xetra close of October 22, 2026. Berenberg maintained its Neutral rating and EUR 3.60 price target on October 16, 2026, according to MarketScreener.

Preliminary revenue beats estimates

Evotec projected EUR 465.0 million in Group revenue for the first nine months of 2026 and adjusted EBITDA of minus EUR 42.8 million. The figures exceeded current market expectations, although the company attributed the variance mainly to the timing of consensus estimates, according to the EQS News release dated October 13, 2026.

What changes before November 5?

Management kept its full-year 2026 revenue outlook at EUR 570 million to EUR 610 million and adjusted EBITDA guidance at minus EUR 70 million to minus EUR 105 million. That leaves the November report as the next test of whether the preliminary revenue advantage reflects operating progress or estimate timing.

Three events set the timeline

On October 13, 2026, Evotec announced preliminary nine-month revenue of EUR 465.0 million. On October 15, 2026, it announced Joanna Holbrook as chief scientific officer, effective November 1, 2026, according to EQS News. On October 16, 2026, Berenberg kept its EUR 3.60 target.

Dates set the next test

Holbrook is scheduled to take office on November 1, 2026. Evotec is scheduled to publish its third-quarter and first nine-month results on November 5, 2026, according to the same company announcement from EQS News.

Price and market value

Evotec's market capitalization was EUR 502.6 million on October 23, 2026, while its 52-week range was EUR 2.41 to EUR 7.30. The stock was trading at EUR 2.83 at Lang & Schwarz on October 23, 2026 at 10:29 a.m. CEST, 0.35 percent below the Xetra close of October 22, 2026 at EUR 2.84. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.